Martine E.D. Chamuleau

3.1k total citations · 1 hit paper
103 papers, 1.6k citations indexed

About

Martine E.D. Chamuleau is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Martine E.D. Chamuleau has authored 103 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pathology and Forensic Medicine, 43 papers in Oncology and 27 papers in Genetics. Recurrent topics in Martine E.D. Chamuleau's work include Lymphoma Diagnosis and Treatment (54 papers), CAR-T cell therapy research (30 papers) and Chronic Lymphocytic Leukemia Research (27 papers). Martine E.D. Chamuleau is often cited by papers focused on Lymphoma Diagnosis and Treatment (54 papers), CAR-T cell therapy research (30 papers) and Chronic Lymphocytic Leukemia Research (27 papers). Martine E.D. Chamuleau collaborates with scholars based in Netherlands, United States and United Kingdom. Martine E.D. Chamuleau's co-authors include Arjan A. van de Loosdrecht, G.J. Ossenkoppele, Theresia M. Westers, Tuna Mutis, Gert J. Ossenkoppele, Hilma J. van der Horst, Pieternella J. Lugtenburg, Adri Zevenbergen, S. Marieke van Ham and Rogier Mous and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Martine E.D. Chamuleau

96 papers receiving 1.6k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martine E.D. Chamuleau Netherlands	21	713	660	586	340	325	103	1.6k
Ilseung Choi Japan	22	692 1.0×	935 1.4×	615 1.0×	213 0.6×	221 0.7×	99	1.7k
Noemí Puig Spain	22	532 0.7×	399 0.6×	393 0.7×	777 2.3×	479 1.5×	111	1.8k
M. Lia Palomba United States	24	1.3k 1.8×	602 0.9×	1.3k 2.1×	312 0.9×	1.1k 3.3×	102	2.5k
Jennifer Barnard United States	14	234 0.3×	1.4k 2.1×	175 0.3×	209 0.6×	258 0.8×	18	2.0k
Weiyun Z. Ai United States	18	977 1.4×	700 1.1×	565 1.0×	207 0.6×	156 0.5×	64	1.5k
Pedro Horna United States	22	550 0.8×	721 1.1×	456 0.8×	252 0.7×	195 0.6×	73	1.5k
Björn E. Wahlin Sweden	18	830 1.2×	493 0.7×	869 1.5×	104 0.3×	337 1.0×	88	1.5k
Carsten Reinhardt Germany	15	1.0k 1.4×	723 1.1×	200 0.3×	454 1.3×	112 0.3×	37	1.7k
Giorgio Inghirami United States	16	401 0.6×	640 1.0×	308 0.5×	231 0.7×	180 0.6×	28	1.3k
Cecilia C.S. Yeung United States	18	1.3k 1.8×	365 0.6×	222 0.4×	392 1.2×	316 1.0×	81	2.0k

Countries citing papers authored by Martine E.D. Chamuleau

Since Specialization

Citations

This map shows the geographic impact of Martine E.D. Chamuleau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martine E.D. Chamuleau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martine E.D. Chamuleau more than expected).

Fields of papers citing papers by Martine E.D. Chamuleau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martine E.D. Chamuleau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martine E.D. Chamuleau. The network helps show where Martine E.D. Chamuleau may publish in the future.

Co-authorship network of co-authors of Martine E.D. Chamuleau

This figure shows the co-authorship network connecting the top 25 collaborators of Martine E.D. Chamuleau. A scholar is included among the top collaborators of Martine E.D. Chamuleau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martine E.D. Chamuleau. Martine E.D. Chamuleau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krens, Stefanie D., et al.. (2025). Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies. British Journal of Clinical Pharmacology. 91(11). 3130–3140.

Linschoten, Marijke, Erik van Werkhoven, Heleen Visser-Wisselaar, et al.. (2025). Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane. Cardio-Oncology. 11(1). 8–8. 2 indexed citations

Duetz, Carolien, Marcel Nijland, Marjolein van der Poel, et al.. (2024). Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS. Blood Advances. 8(5). 1094–1104. 2 indexed citations

McKee, Thomas, Nicolas Mach, Kaveh Samii, et al.. (2024). Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐cell lymphoma: Insights from real‐life clinical practice. Cancer Reports. 7(10). e1983–e1983. 1 indexed citations

Vose, Julie M., Umberto Vitolo, Pieternella J. Lugtenburg, et al.. (2024). EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.. Journal of Clinical Oncology. 42(16_suppl). 7015–7015. 9 indexed citations

Zhong, Yujie, Joost Kluiver, Sanne H. Tonino, et al.. (2023). A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics. Blood Cancer Journal. 13(1). 130–130. 5 indexed citations

Sehn, Laurie H., Martine E.D. Chamuleau, Georg Lenz, et al.. (2023). PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2. Hematological Oncology. 41(S2). 849–850. 4 indexed citations

Westin, Jason R., Caron A. Jacobson, Julio C. Chávez, et al.. (2023). PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA. HemaSphere. 7(S3). e3278692–e3278692. 1 indexed citations

Visser, Otto, Eduardus F. M. Posthuma, Rolf E. Brouwer, et al.. (2022). Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018. Blood Cancer Journal. 12(3). 38–38. 11 indexed citations

10.

Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →

11.

Brink, Mirian, Joost S.P. Vermaat, Josée M. Zijlstra, et al.. (2021). Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Advances. 5(15). 2958–2964. 16 indexed citations

12.

Koens, Lianne, Peter M. van de Ven, Nathalie J. Hijmering, et al.. (2018). Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment. Histopathology. 73(3). 473–482. 10 indexed citations

13.

Oosten, Liesbeth E.M., Martine E.D. Chamuleau, Frederick W. Thielen, et al.. (2017). Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Annals of Hematology. 97(2). 255–266. 26 indexed citations

14.

Chamuleau, Martine E.D., Marcel Nijland, Nathalie J. Hijmering, et al.. (2017). First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands. Blood. 130. 4144–4144.

15.

Horst, Hilma J. van der, Marije B. Overdijk, Esther C.W. Breij, et al.. (2017). Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding. Blood. 130. 1835–1835. 4 indexed citations

16.

Houtenbos, Ilse, Jan Paul de Boer, Aart Beeker, et al.. (2016). Diffuse large B-cell lymphoma with MYC gene rearrangements. European Journal of Cancer. 55. 140–146. 15 indexed citations

17.

Snijders, Dominic, et al.. (2016). Disseminated Mycobacterium chelonae infection in a patient with T-cell lymphoma. Hematology/Oncology and Stem Cell Therapy. 10(2). 89–92. 8 indexed citations

18.

Issa, Djamila E., S.A.M. van de Schans, Martine E.D. Chamuleau, et al.. (2014). Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica. 100(4). 525–533. 37 indexed citations

19.

Luijn, Marvin M. van, Willemijn van den Ancker, Martine E.D. Chamuleau, et al.. (2011). Absence of Class II–Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells. Cancer Research. 71(7). 2507–2517. 23 indexed citations

20.

Kater, Arnon P., S. Wittebol, Martine E.D. Chamuleau, Michel van Gelder, & Marinus H. J. van Oers. (2011). Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011.. Research Publications (Maastricht University). 69(10). 422–9. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact